Full-Text Search:
Home|About CNKI|User Service|中文
Add to Favorite Get Latest Update

THE EFFECTS OF THALIDOMIDE-COMBINATION CHEMOTHERAPY ON CYTOKINE IN PATIENTS WITH MULTIPLE MYELOMA

LIU ZHU-ZHEN,YANG JIE,WANG HONG-YI,et al (Department of Hematology,The Affiliated Hospital of Qingdao University Medical College,Qingdao 266003,China)  
Objective To observe the serum levels of IL-6 and TNF-α in patients with multiple myeloma(MM),and explore the effects of thalidomide-combination chemotherapy on IL-6 and TNF-α.Methods The serum IL-6 and TNF-α in 79 MM patients and 30 normal controls were determined by ELISA,and the results of the patients in different stages as well as before and after therapy were compared.Results The concentrations of IL-6 and TNF-α in MM group were significantly higher than those in the control(t=8.117,11.525;P0.001).The levels of IL-6 and TNF-α in stage Ⅲ and stage Ⅱpatients were higher than those of stageⅠ(F=4.233,10.273;q=3.012-6.294;P0.05).Of 55 patients responding well to the therapy,levels of IL-6 and TNF-α declined significantly compared with before treatment(t=3.153,4.361;P0.01),for 22 patients who showed poor response to the therapy,the serum parameters did not reveal significant difference from that of before medication(t=0.850,0.913;P0.05).Conclusion The concentrations of IL-6 and TNF-α are high in MM patients,and associated with the clinical stages of the disease.The thalidomide-combined chemotherapy can significantly reduce the serum levels of IL-6 and TNF-α,a detection of this two items can be used as an auxiliary index in estimating the therapeutic efficacy and the condition of patients with MM.
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©CNKI All Rights Reserved